Author/Authors :
Tretjakovs, Peteris Riga Stradins University - Chair of Human Physiology and Biochemistry, LATVIA , Tretjakovs, Peteris University of Latvia - Institute of Experimental and Clinical Medicine, LATVIA , Tretjakovs, Peteris Riga Eastern Clinical University Hospital, LATVIA , Jurka, Antra University of Latvia - Institute of Experimental and Clinical Medicine, LATVIA , Jurka, Antra Pauls Stradins Clinical University Hospital, LATVIA , Bormane, Inga University of Latvia - Institute of Experimental and Clinical Medicine, LATVIA , Mikelsone, Indra University of Latvia - Institute of Experimental and Clinical Medicine, LATVIA , Reihmane, Dace University of Latvia - Institute of Experimental and Clinical Medicine, LATVIA , Krievina, Gita University of Latvia - Institute of Experimental and Clinical Medicine, LATVIA , Marksa, Iveta Pauls Stradins Clinical University Hospital, LATVIA , Elksne, Karlina Riga Stradins University - Chair of Human Physiology and Biochemistry, LATVIA , Verbovenko, Jurijs Riga Stradins University - Chair of Human Physiology and Biochemistry, LATVIA , Verbovenko, Jurijs Riga Eastern Clinical University Hospital, LATVIA , Bahs, Guntis Riga Stradins University - Chair of Human Physiology and Biochemistry, LATVIA , Bahs, Guntis Riga Eastern Clinical University Hospital, LATVIA
Abstract :
Recent data indicate that the serum level of neopterin, a marker of inflammation and immune modulator secreted by monocytes/macrophages, is elevated in patients with acute coronary syndrome (ACS) and seems to be a prognostic marker for major cardiovascular events. Soluble cellular adhesion molecules (sCAMs) and myeloperoxidase (MPO) levels are also related to ACS. The aim of the present study was to evaluate differences in serum levels of neopterin, sCAMs and MPO between coronary artery disease and metabolic syndrome (CAD-MetS) patients with stable and unstable angina pectoris (SAP, UAP), and to clarify the relationships between neopterin and other biomarkers. The study included 60 patients with CAD-MetS who were classified into two groups, 30 patients with SAP and 30 patients with UAP. Twenty healthy subjects were selected as controls (C). Serum soluble vascular cell adhesion molecule-1 (sVCAM-1), intercellular cell adhesion molecule-1 (sICAM-1), sE-selectin and MPO levels were measured by Luminex xMAP technology, and serum neopterin concentrations were measured by radioimmunoassay. Results: Serum levels of neopterin, MPO, sVCAM-1, sICAM-1, and sE-selectin were significantly higher in patients with UAP in comparison with the group of healthy controls (P 0.05). Patients with SAP also had higher levels of these biomarkers than those in healthy controls (P 0.05), except for sE-selectin. The biomarker level did not differ between the two patient groups, except for MPO, which was significantly higher in the USP group (P 0.05). Neopterin was significantly correlated only with sVCAM-1 (P 0.05). In conclusion, CAD-Met patients with SAP had more apparent raised levels of serum sICAM-1 and sVCAM-1, simultaneously with higher MPO and neopterin concentrations, in comparison to those in healthy subjects. However, UAP is also associated with more substantial changes in MPO and significantly increased sE-selectin levels. Neopterin concentration was had a close correlation only with sVCAM-1
Keywords :
neopterin , cellular adhesion molecules , myeloperoxidase , angina pectoris , metabolic syndrome , coronary artery disease
